BIOGEN INC. Proceeds from Divestiture of Interest in Consolidated Subsidiaries
BIOGEN INC. (BIIB) reported Proceeds from Divestiture of Interest in Consolidated Subsidiaries of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries · last filed 2026-02-06
- BIOGEN INC. proceeds from divestiture of interest in consolidated subsidiaries for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BIOGEN INC. proceeds from divestiture of interest in consolidated subsidiaries for fiscal 2024 was $406.80M, a 48.38% decline from fiscal 2023.
- BIOGEN INC. proceeds from divestiture of interest in consolidated subsidiaries for fiscal 2023 was $788.10M, a 20.42% decline from fiscal 2022.
- BIOGEN INC. proceeds from divestiture of interest in consolidated subsidiaries for fiscal 2022 was $990.30M.
| Period end | Proceeds from Divestiture of Interest in Consolidated Subsidiaries 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-06 |
| 2024-12-31 | $406.80M 10-K · filed 2026-02-06 |
| 2023-12-31 | $788.10M 10-K · filed 2026-02-06 |
| 2022-12-31 | $990.30M 10-K · filed 2025-02-12 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-14 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |